Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02809911 · ClinicalTrials.gov registry record · NA
A Study to Evaluate PEMF Therapy on Experimentally Inducted Pain in Subjects With Painful Peripheral Diabetic Neuropathy
A NA study, sponsored by Regenesis Biomedical.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT02809911 is a NA study that has completed, run by Regenesis Biomedical. The registered enrollment target is 41 participants.
The verdict
NCT02809911, a NA study, has completed, sponsored by Regenesis Biomedical.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
Evaluate the effectiveness of the Provant Therapy System compared to sham on pain sensitivity and nervous system response to various qualities of experimentally induced pain in the upper and lower extremities of subjects with painful peripheral diabetic neuropathy.
Interventions
- DEVICE Provant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02809911
The ClinicalTrials.gov registry entry for NCT02809911 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regenesis Biomedical, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Provant is the first listed.
NCT02809911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02809911 about?
NCT02809911 is a clinical study titled "A Study to Evaluate PEMF Therapy on Experimentally Inducted Pain in Subjects With Painful Peripheral Diabetic Neuropathy". Evaluate the effectiveness of the Provant Therapy System compared to sham on pain sensitivity and nervous system response to various qualities of experimentally induced pain in the upper and lower extremities of subjects with painful peripheral diabetic neuropathy.
What is the current status of trial NCT02809911?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2016-06. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02809911?
The interventions under investigation include: Provant (DEVICE).
Who is sponsoring clinical trial NCT02809911?
This trial is sponsored by Regenesis Biomedical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.